Phenotypic‐Based Discovery and Exploration of a Resorufin Scaffold with Activity against Mycobacterium tuberculosis
ChemMedChem · 2024
DOI: 10.1002/cmdc.202400482 ↗Kurz gefasst
Fachartikel in der Zeitschrift ChemMedChem, 2024. Verfasst von Eric Tran und 10 weiteren Autor:innen. Beteiligte Einrichtung: Medicinal Chemistry, Monash Institute of Pharmaceutical Sciences, Monash University, Parkville, Victoria, 3052, Australia. Hauptthemen laut MEDLINE: Mycobacterium tuberculosis, Antitubercular Agents, Oxazines, Microbial Sensitivity Tests. Die Arbeit nennt 54 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Newcastle/Monash University Academic Track, Research England.
Abstract (Originalsprache)
Tuberculosis remains a leading cause of death by infectious disease. The long treatment regimen and the spread of drug‐resistant strains of the causative agent Mycobacterium tuberculosis ( Mtb ) necessitates the development of new treatment options. In a phenotypic screen, nitrofuran‐resorufin conjugate 1 was identified as a potent sub‐micromolar inhibitor of whole cell Mtb . Complete loss of activity was observed for this compound in Mtb mutants affected in enzyme cofactor F 420 biosynthesis ( fbiC ), suggesting that 1 undergoes prodrug activation in a manner similar to anti‐tuberculosis prodrug pretomanid. Exploration of the structure‐activity relationship led to the discovery of novel resorufin analogues that do not rely on the deazaflavin‐dependent nitroreductase (Ddn) bioactivation pathway for their antimycobacterial activity. These analogues are of interest as they work through an alternative, currently unknown mechanism that may expand our chemical arsenal towards the treatment of this devastating disease.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Medicinal Chemistry, Monash Institute of Pharmaceutical Sciences, Monash University, Parkville, Victoria, 3052, Australia.
- Department of Microbiology and Immunology, Otago School of Medical Sciences, University of Otago, Dunedin, 9054, New Zealand.
- Department of Microbiology & Immunology, The University of Melbourne at The Peter Doherty Institute for Infection & Immunity, Melbourne, Victoria, 3000, Australia.
- School of Chemistry, University of Melbourne, Parkville, Victoria, 3010, Australia.
- School of Chemistry and Molecular Biosciences, The University of Queensland, Brisbane, Queensland, 4072, Australia.
- Australian Research Council Centre of Excellence for Innovations in Peptide and Protein Science, Monash University, Melbourne, Victoria, 3052, Australia.
ORCID-Profile: Eric Tran, Chen-Yi Cheung, Glen P Carter, Robert W Gable, Nicholas P West, Amandeep Kaur, Yi Sing Gee, Gregory M Cook, Jonathan B Baell, Manuela Jörg
Förderung
- Newcastle/Monash University Academic Track
- Research England
Zitieren
APA
Tran, E., Cheung, C. Y., Li, L., Carter, G. P., Gable, R. W., West, N. P., Kaur, A., Gee, Y. S., Cook, G. M., Baell, J. B., & Jörg, M. (2024). Phenotypic‐Based Discovery and Exploration of a Resorufin Scaffold with Activity against Mycobacterium tuberculosis. ChemMedChem. https://doi.org/10.1002/cmdc.202400482
Vancouver
Tran E, Cheung CY, Li L, Carter GP, Gable RW, West NP, et al. Phenotypic‐Based Discovery and Exploration of a Resorufin Scaffold with Activity against Mycobacterium tuberculosis. ChemMedChem. 2024. doi:10.1002/cmdc.202400482
BibTeX
@article{Tran2024,
author = {Tran, Eric and Cheung, Chen-Yi and Li, Lucy and Carter, Glen P and Gable, Robert W and West, Nicholas P and Kaur, Amandeep and Gee, Yi Sing and Cook, Gregory M and Baell, Jonathan B and Jörg, Manuela},
title = {Phenotypic‐Based Discovery and Exploration of a Resorufin Scaffold with Activity against Mycobacterium tuberculosis},
journal = {ChemMedChem},
year = {2024},
doi = {10.1002/cmdc.202400482}
}
EUVIMED